OTTMUSG00000011268 Inhibitors
Interferon Zeta-like precursor, a vital protein in the immune response, can be functionally inhibited by a range of chemical compounds through various mechanisms. Ruxolitinib and Baricitinib, both JAK inhibitors, act directly on the JAK-STAT signaling pathway, a crucial pathway associated with Interferon Zeta-like precursor regulation. By specifically targeting JAK1 and JAK2, these chemicals disrupt downstream signaling events, effectively inhibiting the functional activity of Interferon Zeta-like precursor. Tofacitinib, another JAK inhibitor, further reinforces this inhibition by targeting JAK1 and JAK3, impeding interferon-induced responses. Fludarabine, a nucleoside analog, indirectly hinders Interferon Zeta-like precursor by interfering with DNA synthesis and repair. This disruption of cellular processes necessary for interferon production and function leads to a functional inhibition of the protein. Curcumin, known for its anti-inflammatory properties, can indirectly inhibit Interferon Zeta-like precursor by modulating signaling pathways, including NF-κB and AP-1, which play roles in interferon regulation. By suppressing these pathways, Curcumin reduces interferon-related responses, contributing to functional inhibition.
Sunitinib, an anti-angiogenic agent, indirectly inhibits Interferon Zeta-like precursor by targeting VEGFR and PDGFR, which are associated with tumor-immune interactions involving the protein. Rapamycin, an mTOR inhibitor, indirectly hampers Interferon Zeta-like precursor by disrupting the mTOR signaling pathway, linked to interferon production. Cycloheximide, a protein synthesis inhibitor, indirectly inhibits the protein by blocking protein translation, reducing overall interferon production, and thus its functional activity within cells. Etanercept, a TNF-α inhibitor, indirectly affects Interferon Zeta-like precursor by modulating the inflammatory environment, which includes cytokine cascades, including interferon pathways. Wortmannin, a PI3K inhibitor, indirectly inhibits the protein by interfering with the PI3K-Akt pathway associated with interferon regulation. AZD1480, a JAK2 inhibitor, primarily targets JAK2 but can also indirectly inhibit Interferon Zeta-like precursor through the JAK-STAT pathway. Finally, SB203580, a p38 MAPK inhibitor, indirectly hampers the protein by disrupting the p38 MAPK signaling pathway, which can be involved in interferon responses. These diverse chemical inhibitors provide valuable insights into the intricate regulation of Interferon Zeta-like precursor, offering potential avenues for further research and understanding of its biological functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib inhibits Interferon Zeta-like precursor by targeting the JAK-STAT signaling pathway, which is known to be involved in the regulation of interferon production. It specifically inhibits JAK1 and JAK2, key components of this pathway, thereby blocking interferon signaling. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib is a JAK inhibitor that can functionally inhibit Interferon Zeta-like precursor by targeting the JAK-STAT pathway. It inhibits JAK1 and JAK2, disrupting the downstream signaling cascade and preventing interferon-induced responses. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Fludarabine is a nucleoside analog that interferes with DNA synthesis and repair. It indirectly inhibits Interferon Zeta-like precursor by disrupting cell cycle progression and impairing the cellular processes required for interferon production and function. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin is known for its anti-inflammatory properties. It can indirectly inhibit Interferon Zeta-like precursor by modulating various signaling pathways, including NF-κB and AP-1, which are involved in interferon regulation. Curcumin's actions result in the suppression of interferon-related responses. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits Interferon Zeta-like precursor through its anti-angiogenic effects. By targeting VEGFR and PDGFR, Sunitinib disrupts the tumor microenvironment and indirectly inhibits interferon signaling, as the protein is often involved in tumor-immune interactions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, can indirectly inhibit Interferon Zeta-like precursor by disrupting the mTOR signaling pathway. This pathway is linked to interferon production, and inhibition of mTOR by Rapamycin reduces interferon levels and its downstream effects. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is a protein synthesis inhibitor that indirectly inhibits Interferon Zeta-like precursor. By blocking protein translation, it reduces the overall levels of interferon production and thus its functional activity within cells. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that indirectly inhibits Interferon Zeta-like precursor by interfering with the PI3K-Akt pathway. This pathway is associated with interferon regulation, and Wortmannin's action on PI3K disrupts interferon signaling and downstream effects. | ||||||
AZD1480 | 935666-88-9 | sc-364735 sc-364735A | 5 mg 50 mg | $124.00 $1072.00 | 11 | |
AZD1480 is a JAK2 inhibitor, and while it primarily targets JAK2, it can also indirectly inhibit Interferon Zeta-like precursor by affecting the JAK-STAT pathway. This leads to the inhibition of interferon signaling and subsequent functional inhibition of the protein. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. It indirectly inhibits Interferon Zeta-like precursor by disrupting the p38 MAPK signaling pathway, which can be involved in interferon responses. Inhibition of p38 MAPK by SB203580 leads to reduced interferon activity and function. | ||||||